Our Services
Medical Information
Helpful Resources
Published on: 8/17/2026
Rapid weight loss on Wegovy or other GLP-1 medications can trigger telogen effluvium, a temporary shedding phase that often shows up first as widening part lines and reduced density at the crown — and for Black women, this diffuse thinning can compound existing traction alopecia or CCCA, making regrowth slower and more visible. The shedding is usually driven by the metabolic stress of fast fat loss plus common nutrient gaps (protein, iron/ferritin, zinc, biotin, vitamin D), not by the drug destroying follicles. Protective steps include slowing the rate of loss, hitting 1.2–1.6 g protein per kg daily, asking for ferritin and thyroid labs, easing tension from braids, weaves, and wigs during the shedding window, and discussing topical minoxidil or anti-inflammatory scalp treatment with a dermatologist familiar with textured hair. Timing, lab thresholds, and how to tell reversible shedding from scarring alopecia are the details that change the outcome, and several factors determine which applies to you — see below to understand more.
If your part looks wider, your ponytail feels thinner, or you're seeing more hair in the shower since starting a GLP-1, it's worth clarifying whether this is expected temporary shedding or an early sign of a scarring condition that needs prompt treatment — because the two have very different windows for intervention. A free, instant, online symptom check can help you organize what you're experiencing, flag patterns worth investigating, and point you toward the right next step and the right kind of clinician to see.
Last reviewed for medical accuracy: 08/16/2026
Doctor’s Note: Will Wegovy Thin Your Crown? How Black Women Can Protect Their Hair Density on GLP-1s
As more Black women turn to GLP-1 medications like Wegovy (semaglutide) for weight management, questions arise about potential hair thinning. While Wegovy has proven benefits for metabolic health and weight loss, a small number of people report hair shedding—often linked to rapid weight loss rather than a direct drug effect. This article explores what we know about Wegovy hair loss in Black women and offers practical, doctor-approved strategies to preserve your crown.
Telogen Effluvium
Why It May Feel More Pronounced in Black Women
Incidence with Wegovy
Nutrition
• Protein deficiency can weaken keratin (hair's main component).
• Iron, zinc, biotin, vitamins D and B12 are essential.
• Rapid weight loss may reduce nutrient stores.
Scalp Health
• A clean, well-circulated scalp supports healthy follicles.
• Over-washing or heavy products can clog follicles.
• Stress reduces circulation and can trigger shedding.
Mechanical & Chemical Stress
• Tight styles (cornrows, buns) exert traction.
• Frequent heat or chemical straightening damages the cuticle.
• Manipulation increases breakage, mimicking thinning.
Optimize Your Diet
Gentle Hair Care Routine
Low-Manipulation Styles
Scalp Stimulation
Supplement Support
Medical Treatments (If Needed)
Even with the best regimen, you may notice some thinning when starting Wegovy. Here’s how to track and respond:
Keep a Hair Log
• Note shampoo days and the amount of shedding (clumps, excess in the drain).
• Photograph your part line every 4–6 weeks.
Evaluate Nutrient Levels
• Schedule blood work for iron, ferritin, vitamin D, B12.
• Discuss any deficiencies with your primary care provider.
Alert Signs to Consult a Doctor
• Sudden, massive shedding (>100 strands per day)
• Bald patches or persistent scalp irritation
• Signs of infection (redness, pain, discharge)
• Dramatic weight loss causing fatigue, dizziness, or heart palpitations
If you’re concerned about hair loss, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker to gauge your needs and next steps.
Wegovy offers substantial metabolic and cardiovascular benefits, including:
In most cases, hair shedding on GLP-1s is temporary and correctable. By focusing on nutrition, gentle hair care, and professional guidance, Black women can protect their hair density while reaping the full benefits of Wegovy.
Wegovy hair loss in Black women is often a result of rapid weight shift and existing hair care stressors. With a proactive plan—nutrient-rich diet, low-manipulation styling, scalp care, and timely medical support—you can maintain a healthy, full crown.
Always speak to a doctor about any serious or life-threatening concerns. If you experience severe symptoms, consult your healthcare provider immediately.
(References)
* Tran MM, Mirza FN, Lee AC, Goldbach HS, Libby TJ, Wisco OJ. Dermatologic findings associated with semaglutide use: A scoping review. J Am Acad Dermatol. 2024 Jul;91(1):166-168. doi: 10.1016/j.jaad.2024.03.021. Epub 2024 Mar 29. PMID: 38554940.
* Desai DD, Sikora M, Nohria A, Bordone L, Caplan AS, Shapiro J, Lo Sicco KI. GLP-1 agonists and hair loss: a call for further investigation. Int J Dermatol. 2024 Sep;63(9):1128-1130. doi: 10.1111/ijd.17246. Epub 2024 May 13. PMID: 38741261.
* Godfrey H, Leibovit-Reiben Z, Jedlowski P, Thiede R. Alopecia associated with the use of semaglutide and tirzepatide: A disproportionality analysis using the FDA adverse event reporting system (FAERS) from 2022 to 2023. J Eur Acad Dermatol Venereol. 2025 Feb;39(2):e153-e154. doi: 10.1111/jdv.20197. Epub 2024 Jun 24. PMID: 38925559.
* Burke O, Sa B, Cespedes DA, Sechi A, Tosti A. Glucagon-like peptide-1 receptor agonist medications and hair loss: A retrospective cohort study. J Am Acad Dermatol. 2025 May;92(5):1141-1143. doi: 10.1016/j.jaad.2025.01.046. Epub 2025 Jan 23. PMID: 39863171.
* Rojas Lopez RF, Lynett Barrera D, Amaya Muñoz MC, Saavedra Diaz MP. Alopecia as an Emerging Adverse Effect Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists for Weight Loss: A Scoping Review. Cureus. 2025 Aug;17(8):e90021. doi: 10.7759/cureus.90021. Epub 2025 Aug 13. PMID: 40951222; PMCID: PMC12431796.
* Tassavor B, Al Salem S. Use of Glucagon-Like Peptide-1 (GLP-1) Agonists in Modulating Preexisting Dermatologic Disease: A Systematic Review. Cureus. 2025 Sep;17(9):e93282. doi: 10.7759/cureus.93282. Epub 2025 Sep 26. PMID: 41020015; PMCID: PMC12466318.
* Camino-Salvador JM, Rodríguez-Cuadrado FJ, Pinto-Pulido EL, Fernández-Parrado M. Glucagon-like peptide-1 receptor agonists and hair loss: An emerging clinical concern. J Eur Acad Dermatol Venereol. 2026 May;40(5):e321-e323. doi: 10.1111/jdv.70088. Epub 2025 Sep 30. PMID: 41025593.
* Burke OM, Sa B, Cespedes DA, Tosti A. Dermatologic Implications of Glucagon-Like Peptide-1 Receptor Agonist Medications. Skin Appendage Disord. 2025 Oct;11(5):416-423. doi: 10.1159/000544023. Epub 2025 Feb 14. PMID: 41058954; PMCID: PMC12500303.
* Alsuwailem OA, Alanazi R, Almutairi HM, Asiree RH, Almutairi W, Almutairi TM, Zamandar A, Alkhames S. Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review. Cureus. 2025 Sep;17(9):e92454. doi: 10.7759/cureus.92454. Epub 2025 Sep 16. PMID: 41111833; PMCID: PMC12530271.
* Gupta AK, Teasell EM, Economopoulos V, Mirmirani P. GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling. Sci Prog. 2026 Apr-Jun;109(2):368504261444578. doi: 10.1177/00368504261444578. Epub 2026 Apr 17. PMID: 41998799; PMCID: PMC13100445.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.